IOL Chemicals IOL Chemicals

X
[{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-\u03b2 Agonist ASC41 for NASH","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Ascletis Pharma"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Obesity Increases Covid Death Rate 10X, ERX Pharmaceuticals Novel Approach & Research Could Be Gamechanger","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"RespireRx Pharmaceuticals"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Janssen Sciences Ireland Unlimited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CinFina Pharma In-Licenses Obesity Portfolio","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"CinRx Pharma"},{"orgOrder":0,"company":"Gmax Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gmax's GMA106, Second Generation Obesity\/T2DM\/NASH mAb Gives First in Human Dose","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Gmax Biopharm"},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Altimmune"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Sciwind"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endevica Bio Doses First Patient in Phase 1 Clinical Trial of TCMCB07 for the Treatment of Cachexia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Endevica Bio"},{"orgOrder":0,"company":"Sciwind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an Oral Small Molecule GLP-1 Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sciwind"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Sirnaomics"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endevica Reports Positive TCMCB07 Data from Single Ascending Dose Portion of Phase 1 Clinical Trial in Cachexia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Endevica Bio"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Presents New AMG 133 Phase 1 Clinical Data AT WCIRDC 2022","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Amgen Inc"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Zealand Pharma"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1\/GIP Receptor Agonist VK2735","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Viking Therapeutics"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1\/GIP Receptor Agonist VK2735","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Viking Therapeutics"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore for the Treatment of Obesity and Associated Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"OrsoBio"},{"orgOrder":0,"company":"MindRank","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"MindRank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces Positive Results From Part 1 Of Multiple Ascending Dose Trial with Amylin Analog ZP8396","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Zealand Pharma"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval from NMPA","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Zhejiang Doer Biologics"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Response Pharmaceuticals"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic\u00ae, Wegovy\u00ae, or Mounjaro\u00ae, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasi","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Veru"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$2,010.0 million","upfrontCash":"$185.0 million","newsHeadline":"Eccogene Enters Exclusive License Agreement with AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Eccogene"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Terns Pharmaceuticals"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$3,100.0 million","upfrontCash":"$2,700.0 million","newsHeadline":"Carmot Therapeutics Enters into Definitive Merger Agreement with Roche","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Carmot Therapeutics"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics to Develop KER-065 for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Keros Therapeutics"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Scholar Rock"},{"orgOrder":0,"company":"Gubra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gubra Announces First Subject Dosed in Phase 1 Clinical Trial of Amylin Agonist (GUBamy) for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Gubra"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            SRK-015 (apitegromab) is an investigational fully human monoclonal antibody inhibiting myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. It is being evaluated in preclinical studies for the treatment of Obesity.

            Lead Product(s): Apitegromab

            Therapeutic Area: Nutrition and Weight Loss Product Name: SRK-015

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 23, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            KER-065 is a novel ligand trap designed to bind to and inhibit TGF-ß ligands, including myostatin (GDF8) and activin A. It is being evaluated for the treatment of obesity.

            Lead Product(s): KER-065

            Therapeutic Area: Nutrition and Weight Loss Product Name: KER-065

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 03, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the acquisition, Roche will build its portfolio by adding Carmot’s pipeline of GLP-1/GIP receptor agonist, including CT-388, CT-996 and CT-868 which are being evaluated for the treatment of metabolic diseases including obesity and diabetes.

            Lead Product(s): CT-388

            Therapeutic Area: Nutrition and Weight Loss Product Name: CT-388

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: $3,100.0 million Upfront Cash: $2,700.0 million

            Deal Type: Acquisition December 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            GUBamy (GUB014295) is a long-acting amylin agonist for once weekly subcutaneous administration. It is under phase 1 clinical development for the potential treatment of obesity.

            Lead Product(s): GUB014295

            Therapeutic Area: Nutrition and Weight Loss Product Name: GUBamy

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AstraZeneca will receive an exclusive license to develop and commercialize ECC5004, a small molecule GLP-1 receptor agonist, for the potential treatment of obesity, type-2 diabetes and other comorbidities, in all territories except China.

            Lead Product(s): ECC5004

            Therapeutic Area: Nutrition and Weight Loss Product Name: ECC5004

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: $2,010.0 million Upfront Cash: $185.0 million

            Deal Type: Licensing Agreement November 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TERN-601 is an oral, small-molecule glucagon-like peptide-1 receptor, or GLP-1R, agonist program for obesity. Obesity is a chronic disease that is increasing in prevalence in adults, adolescents and children and is often defined by having an elevated BMI of 30 or greater.

            Lead Product(s): TERN-601

            Therapeutic Area: Nutrition and Weight Loss Product Name: TERN-601

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            VERU-024 (enobosarm), a selective androgen receptor modulator, into a Phase 2b clinical trial in combination with semaglutide to evaluate the efficacy and the safety of enobosarm to further increase fat loss.

            Lead Product(s): Enobosarm,Abemaciclib,Tirzepatide

            Therapeutic Area: Nutrition and Weight Loss Product Name: VERU-024

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            RDX-002 is a first-in-class, potent, and selective inhibitor of intestinal MTP. iMTP is a protein believed to be a key driver of weight gain and metabolic dysregulation in patients treated with antipsychotic drugs for schizophrenia, major depressive disorder.

            Lead Product(s): RDX-002

            Therapeutic Area: Nutrition and Weight Loss Product Name: RDX-002

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonizing GLP-1R, glucagon receptor GCGR, and FGF21R, which is investigated for the treatment of obesity and hypertriglyceridemia in New Zealand.

            Lead Product(s): DR10624

            Therapeutic Area: Nutrition and Weight Loss Product Name: DR10624

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 01, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ZP8396 is an investigational, potent long-acting amylin analogue designed to improve solubility, minimize fibrillation and allow for co-formulation with other peptides, including GLP-1 analogues, it holds potential for the treatment of obesity.

            Lead Product(s): ZP8396

            Therapeutic Area: Nutrition and Weight Loss Product Name: ZP8396

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY